Cortiflam

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cortiflam

What is Cortiflam? An Overview

Cortiflam, whose active component is Betamethasone Dipropionate, is a highly potent, synthetic medication primarily used to manage severe inflammation and immune responses.

Quick Facts

Property Description
Active ingredient Betamethasone Dipropionate
Form Oral tablet, Topical (cream, ointment, gel, lotion)
Pharmacological class Corticosteroid (Synthetic Glucocorticoid)
General purpose Anti-inflammatory and Immunosuppressive action
Origin Synthetic (Fluorinated steroid)

Cortiflam: A Synthetic Corticosteroid and Its Core Identity

Cortiflam is the trade name for a medicinal preparation whose primary active ingredient is Betamethasone Dipropionate, classifying it as a synthetic glucocorticoid within the Corticosteroid pharmacological class. This means the drug is an artificially created compound, a modified ester of betamethasone, designed to emulate and significantly enhance the anti-inflammatory and immunosuppressive properties of natural adrenal hormones.

As a high-potency agent, Cortiflam provides a robust pharmaceutical tool for managing severe inflammatory responses. The compound Betamethasone Dipropionate is specifically recognized as a fluorinated steroid, a chemical structure that contributes to its increased effectiveness and stability compared to non-fluorinated analogues. It is typically a single-ingredient product, which focuses the entire therapeutic action on achieving a strong anti-inflammatory action and immunosuppressive action for conditions requiring intensive control of inflammation. Corticosteroids serve as therapeutic agents for conditions requiring the suppression of inflammation and immune responses.


Forms, Composition, and General Purpose

Cortiflam preparations are available in various common dosage forms, including the oral tablet for systemic effects and numerous topical preparations, such as creams, ointments, gels, and lotions, intended for dermal application. The topical formulations of Betamethasone Dipropionate are clinically recognized for their high skin penetration and retention, making them a preferred choice when powerful localized action is required.

The final composition combines the active ingredient with a specific pharmaceutical base/vehicle such as an emulsified base for creams or standard excipients for tablets. The general purpose of administering the drug is to deliver a potent agent that effectively reduces the core symptoms of conditions linked to high inflammation and immune hyperactivity, including excessive swelling, redness, and persistent itching, providing significant symptomatic relief.

Regulatory References

  1. WHO Model List of Essential Medicines
  2. WHO Essential Medicines List

What side effects are possible with Cortiflam?

Possible Side Effects and Safety Information

The safety profile of Cortiflam is largely determined by its component drugs: a corticosteroid (e.g., Betamethasone) and an antihistamine (e.g., Dexchlorpheniramine).

Common Adverse Reactions

Component Common Effects
Corticosteroid Weight gain, mood and behavioral changes, headache, dizziness, bone density reduction, easy bruising, and upset stomach. Long-term use or high doses can increase the risk of these effects.
Antihistamine Drowsiness, dizziness, dry mouth, blurred vision, headache, and constipation. These effects may impair the ability to drive or operate machinery.

Serious and Clinically Significant Adverse Reactions

Serious reactions linked to the corticosteroid component include Cushing syndrome (due to prolonged exposure), glaucoma or cataract, severe gastrointestinal ulceration, and Hypothalamic-pituitary-adrenal (HPA) axis suppression. The antihistamine component can, in rare cases, be associated with serious central nervous system effects or cardiac irregularities like Arrhythmia.

Safety Considerations and Limitations

  • Pregnancy and Breastfeeding: Use of the corticosteroid component during pregnancy is generally not recommended unless the benefit outweighs the potential risk. Both components require caution during breastfeeding.
  • Pre-existing Conditions: The medicine is generally contraindicated or requires particular caution in patients with uncontrolled systemic infections, diabetes, high blood pressure, glaucoma, osteoporosis, and certain gastrointestinal or liver problems.
  • Withdrawal: Abrupt discontinuation of the corticosteroid component after prolonged use can lead to serious withdrawal symptoms, and a gradual tapering schedule is typically required.
  • Alcohol: Consumption of alcohol is strongly advised against, as it can significantly enhance the sedative effects of the antihistamine component.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Cortiflam based on documented clinical experience and expected pharmacological effects at supratherapeutic levels. This information is intended for use by healthcare professionals in emergency situations.

Documented Overdose Manifestations

Symptoms and signs of overdose are typically an exaggeration of the drug's known adverse reactions. Manifestations often involve severe effects on the central nervous system (CNS) and the cardiovascular system. Specific symptoms may include profound sedation, confusion, marked changes in heart rate, and very low blood pressure (hypotension).

When Immediate Medical Help Is Required

Immediate emergency medical attention must be sought for signs of severe intoxication. These critical outcomes indicate an urgent, life-threatening situation and include:

  • Respiratory Depression: Slowed, shallow, or difficult breathing.
  • Unresponsiveness: Inability to wake up or respond to verbal or physical stimuli.
  • Circulatory Collapse: Signs of severe weakness, dizziness, or fainting due to very low blood pressure.

Emergency Management

Management of a Cortiflam overdose is primarily supportive. The key focus is on maintaining adequate respiratory and circulatory functions. The official labeling specifies that, if applicable, a specific antidote or activated charcoal may be considered to reduce systemic exposure, depending on the dose ingested and the time elapsed. Patients require a period of observation to monitor for potential delayed toxic effects.

Therapeutic Uses of Cortiflam

What Cortiflam Treats: Main Uses and Benefits

Cortiflam, a potent synthetic corticosteroid, is commonly used across therapeutic domains involving heightened responses, where additional symptomatic support is needed. The therapeutic benefit is primarily focused on providing support that helps ease the overall symptom burden for symptoms that interfere with daily comfort. The active ingredient is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.


Cortiflam is commonly used across domains where additional symptomatic support is needed, such as in the symptomatic management of corticosteroid-responsive dermatoses, including significant forms of plaque psoriasis and acute eczematous disorders. Its use may be relevant in systemic contexts, such as addressing the symptoms related to acute manifestations of allergic reactions or supporting symptom management during flare-ups in certain systemic inflammatory disorders.

It is used for managing clusters of symptoms that may be associated with these chronic conditions, which often include the intense, persistent itching (pruritus), pronounced redness (erythema), swelling, and skin changes like scaling or crusting.

“This application contributes to easing the overall symptom load of distressing skin manifestations, helping patients cope more steadily with symptom fluctuations.”

This application supports general well-being during symptomatic phases by providing assistance in the management of these challenging symptomatic phases, relevant when short-term symptomatic assistance is needed.

Quick Fact: Symptom Support
Cortiflam is commonly applied when symptoms create noticeable physiological strain and require anti-inflammatory support, relevant in conditions characterized by periods of heightened symptoms.

Regulatory References

  1. NIH DailyMed Label: BETAMETHASONE DIPROPIONATE cream

Eligibility and Restrictions for Use

Cortiflam, a potent corticosteroid, has specific, regulatory-mandated population rules that determine eligibility for use. These rules are detailed in official government labeling.

Populations Who Must Not Use Cortiflam (Contraindications)

Use is strictly contraindicated if a patient has a known hypersensitivity (allergy) to the active component, Betamethasone Dipropionate, or any other ingredient in the preparation. It must not be used to treat conditions like rosacea or perioral dermatitis. Furthermore, topical formulations are explicitly prohibited for use in the eyes, mouth, or vagina, or for the treatment of diaper rash in infants.

Age-Related and Conditional Restrictions

Eligibility is largely dependent on age and co-existing conditions, which impose regulatory limitations.

Eligibility Status Population/Condition Restriction Reason
Not Recommended Children 12 and younger Higher risk of systemic toxicity.
Conditional Use Pregnant Women Use only if potential benefit justifies risk to the fetus.
Caution Advised Nursing Mothers Unknown if quantities pass into breast milk.
Conditional Use Liver Failure, Diabetes Increased risk of systemic side effects.

Use on sensitive areas like the face, groin, and armpits is also generally avoided according to official labeling restrictions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Cortiflam, whose active ingredient is Betamethasone Dipropionate, outlines specific combinations and conditions that affect the drug’s exposure and risk profile.

Contraindicated and High-Risk Combinations

Co-administration with Mifepristone is formally designated as a contraindicated combination by regulatory authorities. This restriction is based on the potential for altered effects when systemic corticosteroids are combined with Mifepristone.

Pharmacokinetic and Pharmacodynamic Interactions

The clearance of Cortiflam is reduced when co-administered with Potent CYP3A4 Inhibitors (e.g., ritonavir or cobicistat). This pharmacokinetic interaction results in increased plasma concentration (exposure) of Cortiflam. This is a documented risk of reduced metabolic clearance.

A separate pharmacodynamic interaction exists with Quinolone Antibiotics (fluoroquinolones). Regulatory sources note that the combination increases the documented risk of tendon rupture. A similar pharmacodynamic consideration involves Non-depolarizing Neuromuscular Blockers, where co-administration carries an officially noted increased risk of acute myopathy.

Population-Specific Considerations

Regulatory labeling highlights that systemic exposure risk is elevated in patients with Liver Failure or Hepatic Impairment due to reduced drug clearance. Pediatric patients are also noted to be more susceptible to systemic toxicity and potential HPA axis suppression.

Mechanism of Action

Cortiflam is a synthetic glucocorticoid agonist that rapidly diffuses across the cell membrane to bind with high affinity to the cytoplasmic glucocorticoid receptor (GR). This interaction initiates the dissociation of the receptor-ligand complex from heat-shock proteins (HSPs). The activated GR-Cortiflam complex then translocates to the cell nucleus.

In the nucleus, the complex acts primarily to modulate gene transcription via two main mechanisms. First, through Transrepression, the complex interacts with transcription factors such as NF-kappaB and AP-1, inhibiting their binding to DNA. This action represses the transcription of key pro-inflammatory genes (e.g., IL-1, IL-6, TNF-alpha, and COX-2). Second, through Transactivation, the complex binds to specific glucocorticoid response elements (GREs) in promoter regions, upregulating the transcription of anti-inflammatory proteins (e.g., Ikappa Balpha and lipocortin/annexin A1).

The net result of these intracellular interactions is a comprehensive modulation of inflammatory processes at the cellular level, which secondarily influences osteoclast differentiation and activity.

Dosage and Administration Information

How Cortiflam is Used: Official Administration Guidelines

Cortiflam, whose active ingredient is Betamethasone Dipropionate, is classified as a high-potency topical medication. Its use is governed by specific instructions concerning the method, amount, frequency, and duration of application, as established in prescribing information.


Administration Scope

Instruction Category Official Label-Based Guideline (Betamethasone Dipropionate)
Route of administration Topical (Dermal application) only.
Dosing schedule Apply a thin film (cream/ointment) or few drops (lotion) to the affected skin area.
Frequency pattern Application is typically once daily or twice daily, depending on the formulation.
Age-group rules Indicated for patients 13 years of age and older. Use in younger children is restricted and not recommended for certain pediatric conditions.

Procedural Constraints and Duration Limits

Official instructions impose specific constraints on application and duration. The medication is used for a short-term course and is not intended for continuous, long-term use. Total application duration must generally not exceed two to four consecutive weeks, and the total amount used is strictly limited to 50 grams (or 50 mL) per week.

Procedurally, the product is for external use only and must not be applied to sensitive areas, including the face, groin, or axillae. Use with occlusive dressings (e.g., plastic wraps or tight bandages) is prohibited unless directed by a physician, as this increases systemic exposure. Treatment should be discontinued once adequate control of the skin condition is achieved.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cortiflam

Evidence for Use in Plaque Psoriasis and Eczematous Disorders

The clinical evaluation for Cortiflam's active component, Betamethasone Dipropionate, relies mainly on short-term Randomized Controlled Trials (RCTs). These studies was evaluated in populations of adults and some pediatric subjects with conditions characterized by fluctuating or episodic manifestations, such as plaque psoriasis and eczematous disorders.

Researchers monitored outcomes related to physical discomfort, including itching, redness, and plaque thickness, to describe changes in skin status over defined treatment intervals. Research reports detailed various outcomes reflecting daily functioning or activity level that was observed in the studied groups over these short periods.


Long-term Studies and Follow-up Evidence

The active treatment phases in the key clinical evaluation trials are typically short, meaning follow-up durations were limited, often to a few weeks. Long-term outcomes are not fully established regarding the sustained response patterns or what patterns of symptom activity may be observed after treatment is stopped. Data for certain groups remain insufficient when considering continuous or repeated use over extended periods.


Research in Special Populations and Uncertainties

Research has explored specific groups, notably by including pediatric subjects (teenagers) in clinical studies. However, primary evidence generally focuses on broadly defined adult populations. Data for certain groups remain insufficient (e.g., the very elderly), and subgroup findings are uncertain.

The available research provides context but not individual predictions. A significant descriptive limitation is that the long-term effects are not fully established, and evidence quality varies across studies, meaning research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Betamethasone Dipropionate Cream USP, 0.05% Official Prescribing Information (Indications, Clinical Studies, Pediatric Use)
  2. Topical Corticosteroids (NIH/StatPearls - Summary of evidence, pediatric risk factors, and long-term use concerns)

Frequently Asked Questions (FAQ)

Common questions about Cortiflam (FAQ)


Q: Why is Cortiflam prescribed for certain conditions?

A: Regulatory documents state that Cortiflam is indicated for the relief of the inflammatory and itching manifestations of certain skin conditions (dermatoses) that respond to treatment with a type of medicine called corticosteroids. Its main purpose is described as reducing inflammation and related symptoms like persistent itching.


Q: Can Cortiflam be used for pain relief?

A: The official product information lists the indications for Cortiflam as the relief of inflammatory and pruritic (itching) manifestations of skin conditions. The labeling does not explicitly state its use for general pain relief, though the reduction of inflammation is known to help relieve discomfort.


Q: How quickly does Cortiflam start to work after I take it?

A: For most topical treatments like Cortiflam, clinical data suggests that improvement in skin conditions is often noted within three to four days of starting application. The full benefit may take a longer period to be observed.


Q: Can Cortiflam be taken by people with kidney issues?

A: Official information for the active component, Betamethasone, suggests that caution or potential dosage adjustment may be necessary for patients with kidney disease. The need for potential dosage adjustment or caution in patients with kidney issues emphasizes the importance of clinical oversight.


Q: I'm taking a blood thinner, can Cortiflam interact with it?

A: Official regulatory sources note that corticosteroids may alter the effects of certain blood thinners, particularly Warfarin. This combination is associated with an increased documented risk of bleeding, and the need for close monitoring of blood clotting levels is noted in the event of co-administration.


Q: Is Cortiflam safe to take with food or on an empty stomach?

A: For the oral form, the product label generally does not indicate a specific requirement to take it with food or on an empty stomach. However, the official documentation indicates the importance of clinical oversight regarding patient diet when using the oral formulation.


Q: Is Cortiflam a prescription-only medicine?

A: Formulations containing the potent active ingredient Betamethasone Dipropionate are typically regulated and available by prescription only (Rx) in many regions. Official regulatory decisions establish its status as a prescription medicine.


Q: Are there any known foods or drinks that interact with Cortiflam?

A: Official documentation notes that alcohol consumption is associated with a risk of significantly increased sedation when co-administered with the antihistamine component. While the oral form does not usually have specific food restrictions, the importance of clinical oversight regarding patient diet is indicated.


Q: Is Cortiflam used to treat fevers?

A: No, Cortiflam is not indicated for the treatment of fevers. According to the official product information, its indications are specifically for the relief of inflammatory and itching manifestations of certain skin conditions that respond to corticosteroid treatment.


Q: Can someone with heart conditions use Cortiflam?

A: Official prescribing information advises caution for patients with heart problems or high blood pressure (hypertension). This is due to the documented potential for fluid and sodium retention, or other cardiac irregularities associated with corticosteroid use, particularly at higher systemic absorption levels.


Q: What is the function of the inactive ingredients in Cortiflam tablets?

A: Inactive ingredients, often called excipients or a base, are combined with the active drug to achieve the final pharmaceutical form (e.g., tablet, cream). They are not intended to have a therapeutic action, but they play a necessary role in the drug's stability, absorption, and overall function.


Q: Are there different strengths of Cortiflam available?

A: Yes, regulatory documents note that different topical formulations of Betamethasone Dipropionate are available in varying strengths, such as a 0.05% cream. These strengths correspond to different labeled potencies of the medication.


Q: Can I use over-the-counter supplements while taking Cortiflam?

A: Regulatory warnings typically focus on specific drug-to-drug interactions. The regulatory documents suggest that clinical oversight should be maintained regarding all supplements, herbal remedies, and complementary medicines being used, as sufficient data on all possible combinations may be limited.


Q: Does the time of day matter when taking Cortiflam?

A: The official instructions for topical application state to apply the product once or twice daily, depending on the formulation. However, the labeling does not specify a particular time of day (such as morning or night) when the drug must be administered.


Q: Why are routine tests sometimes needed when using Cortiflam?

A: Routine tests, such as blood work, may be recommended to monitor for potential internal side effects when Cortiflam is used over large areas or for extended periods. This monitoring helps check for conditions like Hypothalamic-Pituitary-Adrenal (HPA) axis suppression or changes in blood sugar (hyperglycemia) that can result from the drug’s absorption into the body.


Q: Does Cortiflam have a black box warning?

A: The FDA label for the active component, Betamethasone Dipropionate, does not contain a Black Box Warning. A Black Box Warning represents the most severe type of safety warning required by the FDA to call attention to serious or life-threatening risks.


Q: Can elderly patients use Cortiflam?

A: Research documents note that data for certain groups, including the very elderly, may be insufficient to fully establish the response patterns. The possibility of increased susceptibility to systemic side effects suggests the need for clinical oversight when used by the elderly.

How should Cortiflam be stored and disposed of?

How to Store and Dispose of Cortiflam?

This section outlines the official requirements for the storage and final disposal of Cortiflam, based on government regulatory documentation.

Official Storage and Handling

Requirement Official Statement
Temperature & Environment Store at room temperature in a cool and dry place.
Child Safety Keep it out of reach of children and pets.
Container Integrity Containers must provide adequate protection and must not alter the drug’s identity, strength, or purity.
Improper Conditions Products exposed to improper conditions (e.g., extreme heat, fumes) must not be salvaged.

Official Disposal Rules

  • Preferred Method: The primary method for disposal is using a drug take-back program or mail-back service.
  • Household Disposal: If no take-back program is available, mix the medicine (do not crush tablets) with an unappealing substance, such as dirt or used coffee grounds, seal the mixture in a plastic bag, and place it in the household trash.
  • Expiration: Dispose of expired medicines as they may lose effectiveness or safety.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cortiflam found in:

A-Z Index: